Your browser doesn't support javascript.
loading
Immunotherapy for esophageal cancer: Where are we now and where can we go.
Shoji, Yoshiaki; Koyanagi, Kazuo; Kanamori, Kohei; Tajima, Kohei; Ogimi, Mika; Ninomiya, Yamato; Yamamoto, Miho; Kazuno, Akihito; Nabeshima, Kazuhito; Nishi, Takayuki; Mori, Masaki.
Afiliación
  • Shoji Y; Department of Gastroenterological Surgery, Tokai University School of Medicine, Kanagawa 259-1193, Japan.
  • Koyanagi K; Department of Gastroenterological Surgery, Tokai University School of Medicine, Kanagawa 259-1193, Japan. kkoyanagi@tsc.u-tokai.ac.jp.
  • Kanamori K; Department of Gastroenterological Surgery, Tokai University School of Medicine, Kanagawa 259-1193, Japan.
  • Tajima K; Department of Gastroenterological Surgery, Tokai University School of Medicine, Kanagawa 259-1193, Japan.
  • Ogimi M; Department of Gastroenterological Surgery, Tokai University School of Medicine, Kanagawa 259-1193, Japan.
  • Ninomiya Y; Department of Gastroenterological Surgery, Tokai University School of Medicine, Kanagawa 259-1193, Japan.
  • Yamamoto M; Department of Gastroenterological Surgery, Tokai University School of Medicine, Kanagawa 259-1193, Japan.
  • Kazuno A; Department of Gastroenterological Surgery, Tokai University School of Medicine, Kanagawa 259-1193, Japan.
  • Nabeshima K; Department of Gastroenterological Surgery, Tokai University School of Medicine, Kanagawa 259-1193, Japan.
  • Nishi T; Department of Gastroenterological Surgery, Tokai University School of Medicine, Kanagawa 259-1193, Japan.
  • Mori M; Department of Gastroenterological Surgery, Tokai University School of Medicine, Kanagawa 259-1193, Japan.
World J Gastroenterol ; 30(19): 2496-2501, 2024 May 21.
Article en En | MEDLINE | ID: mdl-38817664
ABSTRACT
Immune checkpoint inhibitor therapy has dramatically improved patient prognosis, and thereby transformed the treatment in various cancer types including esophageal squamous cell carcinoma (ESCC) in the past decade. Monoclonal antibodies that selectively inhibit programmed cell death-1 (PD-1) activity has now become standard of care in the treatment of ESCC in metastatic settings, and has a high expectation to provide clinical benefit during perioperative period. Further, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody has also been approved in the treatment of recurrent/metastatic ESCC in combination with anti-PD-1 antibody. Well understanding of the existing evidence of immune-based treatments for ESCC, as well as recent clinical trials on various combinations with chemotherapy for different clinical settings including neoadjuvant, adjuvant, and metastatic diseases, may provide future prospects of ESCC treatment for better patient outcomes.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Terapia Neoadyuvante / Antígeno CTLA-4 / Carcinoma de Células Escamosas de Esófago / Inhibidores de Puntos de Control Inmunológico / Inmunoterapia Límite: Humans Idioma: En Revista: World J Gastroenterol Asunto de la revista: GASTROENTEROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Terapia Neoadyuvante / Antígeno CTLA-4 / Carcinoma de Células Escamosas de Esófago / Inhibidores de Puntos de Control Inmunológico / Inmunoterapia Límite: Humans Idioma: En Revista: World J Gastroenterol Asunto de la revista: GASTROENTEROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos